Bacteriophage Drug Development and Regulatory Affairs with Dr. Carrie-Lynn Langlais Furr, CEO and Co-founder at Bacteriophage & Drug Development Consultants (BDDC)
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Bacteriophage Drug Development and Regulatory Affairs with Dr. Carrie-Lynn Langlais Furr, CEO and Co-founder at Bacteriophage & Drug Development Consultants (BDDC)
-
ナレーター：
-
著者：
このコンテンツについて
As more phage-based and phage-derived products and therapies emerge, swift decisions and strategies in drug development, designing clinical trials and approaching regulatory agencies come in handy. In this week's Phage Therapy Today, we sit down with Dr. Carrie-Lynn Langlais Furr, coming from a solid bacteriophage science background and coming with more than a decade's experience in phage related drug development and regulatory affairs, to talk about her advise on how to navigate these waters. Let's give it a listen to what some potential challenges lay ahead of us and how to be better prepared.
Find out more about Dr. Furr and her company Bacteriophage & Drug Development Consultants (BDDC) @https://www.linkedin.com/in/bacteriophage-and-drug-development-consultants/